These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11426652)

  • 1. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
    Kirn D
    Oncogene; 2000 Dec; 19(56):6660-9. PubMed ID: 11426652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replicating adenoviruses in cancer therapy.
    Dobbelstein M
    Curr Top Microbiol Immunol; 2004; 273():291-334. PubMed ID: 14674605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
    Gomez-Manzano C; Balague C; Alemany R; Lemoine MG; Mitlianga P; Jiang H; Khan A; Alonso M; Lang FF; Conrad CA; Liu TJ; Bekele BN; Yung WK; Fueyo J
    Oncogene; 2004 Mar; 23(10):1821-8. PubMed ID: 15014451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent replicative delta-24 adenoviral vector driven by the promoter of human papillomavirus 16 that is highly selective for associated neoplasms.
    Delgado-Enciso I; Cervantes-García D; Martínez-Dávila IA; Ortiz-López R; Alemany-Bonastre R; Silva-Platas CI; Lugo-Trampe A; Barrera-Saldaña HA; Galván-Salazar HR; Coronel-Tene CG; Sánchez-Santillán CF; Rojas-Martínez A
    J Gene Med; 2007 Oct; 9(10):852-61. PubMed ID: 17729237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter.
    Nettelbeck DM; Rivera AA; Balagué C; Alemany R; Curiel DT
    Cancer Res; 2002 Aug; 62(16):4663-70. PubMed ID: 12183423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.
    Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS
    Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors.
    Wang Y; Xue SA; Hallden G; Francis J; Yuan M; Griffin BE; Lemoine NR
    Cancer Res; 2005 Feb; 65(4):1523-31. PubMed ID: 15735041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
    Kim J; Cho JY; Kim JH; Jung KC; Yun CO
    Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
    Bauerschmitz GJ; Barker SD; Hemminki A
    Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn D
    Gene Ther; 2001 Jan; 8(2):89-98. PubMed ID: 11313778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectively replicating oncolytic adenoviruses as cancer therapeutics.
    Yu DC; Working P; Ando D
    Curr Opin Mol Ther; 2002 Oct; 4(5):435-43. PubMed ID: 12435044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
    Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
    Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
    Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
    Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D
    Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.